BRAIN Biotech AG
General | General InformationGeneral Information
| Company name | BRAIN Biotech AG |
|
| Company website | www.brain-biotech-group.com | |
| Number of employees | 250 - 499 | |
| Reporting year | 2022 | |
| Indicator set | GRI SRS | |
| Directly affected by the disclosure of non-financial and diversity information | No | |
| Reporting on EU taxonomy | not subject to the reporting obligation and not reporting according to EU taxonomy | |
| Contact |
BRAIN Biotech AG
Associate Manager ESG & Sustainability Almut Kohl Darmstädter Straße 34-36 64673 Zwingenberg Germany +49-6251-9331-0 alk@brain-biotech.com |
|
Describe your business model (including type of company, products / services)
BRAIN Biotech AG is a leading European specialist in industrial biotechnology. The business model is based on the identification, development and utilization of biological knowledge and natural resources for various applications in the fields of health, nutrition, chemistry and the environment. With these bio-based solutions, BRAIN seeks to contribute to a more sustainable economy. BRAIN Holding, based in Zwingenberg (Germany) is the mother company of the BRAIN Group.
The company pursues an approach known as the "bioeconomy." This means that it uses biological resources, such as microorganisms, enzymes and other biological components, to develop innovative solutions for a wide range of industries. BRAIN Biotech AG works with partners from various industries to develop tailored solutions for their specific needs. This may involve the development of new enzymes for industrial processes, the production of ingredients for food and cosmetics, or the discovery of new active ingredients for the pharmaceutical industry.
The business of the BRAIN Group is formed by three pillars: (1) the BioScience, (2) the BioProducts and (3) BioIncubator segment. BioScience comprises contract research for renowned industrial partners The BioScience segment is mainly served by the Zwingenberg site in Germany. In the BioIndustrial segment, the company focuses on the specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the corresponding distribution. This is covered by five additional proprietary production sites in continental Europe, the UK and the USA. These production sites, together with the associated biotechnological production know-how, complete the value chain within the Group. The BioIncubator segment marks the development of our own highly innovative products. In the incubator, we develop breakthrough products and services with high economic potential and a positive impact on the environment.
The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN takes on technological challenges and develops biobased products and solutions that are already being successfully used in industry.
In summary, BRAIN Biotech AG generates revenues through various business activities, including:
1. research and development services for industry partners.
2. licensing of developed technologies, enzymes or active ingredients.
3. sale of products resulting from the company's own research findings, such as enzymes for industrial applications or ingredients for food and cosmetics.
In the financial year 2021/22, BRAIN Biotech AG generated revenues of EUR 49.5 million with an adjusted EBITDA loss of EUR 0.1 million, representing a 29% increase in revenues compared to the financial year 20/21. While our underlying business segments BioScience and BioIndustrial are both profitable, we continue to invest more in our incubator pipeline, our future growth and value driver, than we currently generate in our operating business. Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).
The company pursues an approach known as the "bioeconomy." This means that it uses biological resources, such as microorganisms, enzymes and other biological components, to develop innovative solutions for a wide range of industries. BRAIN Biotech AG works with partners from various industries to develop tailored solutions for their specific needs. This may involve the development of new enzymes for industrial processes, the production of ingredients for food and cosmetics, or the discovery of new active ingredients for the pharmaceutical industry.
The business of the BRAIN Group is formed by three pillars: (1) the BioScience, (2) the BioProducts and (3) BioIncubator segment. BioScience comprises contract research for renowned industrial partners The BioScience segment is mainly served by the Zwingenberg site in Germany. In the BioIndustrial segment, the company focuses on the specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the corresponding distribution. This is covered by five additional proprietary production sites in continental Europe, the UK and the USA. These production sites, together with the associated biotechnological production know-how, complete the value chain within the Group. The BioIncubator segment marks the development of our own highly innovative products. In the incubator, we develop breakthrough products and services with high economic potential and a positive impact on the environment.
The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN takes on technological challenges and develops biobased products and solutions that are already being successfully used in industry.
In summary, BRAIN Biotech AG generates revenues through various business activities, including:
1. research and development services for industry partners.
2. licensing of developed technologies, enzymes or active ingredients.
3. sale of products resulting from the company's own research findings, such as enzymes for industrial applications or ingredients for food and cosmetics.
In the financial year 2021/22, BRAIN Biotech AG generated revenues of EUR 49.5 million with an adjusted EBITDA loss of EUR 0.1 million, representing a 29% increase in revenues compared to the financial year 20/21. While our underlying business segments BioScience and BioIndustrial are both profitable, we continue to invest more in our incubator pipeline, our future growth and value driver, than we currently generate in our operating business. Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).
Additional remarks:
BRAINimpact
Today we directly address at least five of the UN Sustainability Development Goals by our products and services. We really can make a difference with solutions for the SDGs 2, 3, 6, 9 and 12. Most of our impact services and products are developed within our incubator pipeline. In our incubator we currently have eleven programs at different stages of maturity. All of them address big societal topics in the areas of nutrition, health and environment. By this our products and services directly contribute to a more sustainable lifestyle, better health, the preservation of primary resources and, with our genome engineering platform, offer a basis technology also applicable to the important biologization of industrial processes.